Introduction
Evidence-based medicine involves the synthesis and interpretation of existing evidence, with the goal being to take those scientific aspects of medicine and formalize them, so as to rationalize the decisions being made (e.g., by providers, insurers, regulators) and, ultimately, improve patient outcomes. An example is a structured literature review performed to support a technology assessment. Most reviews include two components. The first component is a synthesis of the literature using evidence tables or a quantitative meta-analysis. The second component involves using the evidence tables or meta-analysis to develop consensus statements and coverage decisions. The second component can include a description of gaps in the existing literature and potential studies that can address these gaps.
Some elements of these processes are specified to a high degree, while others are not. For example, the rules by which literature searches should be reported are very precisely specified, as are the statistical algorithms for performing a meta-analysis. In contrast, the linkage between gaps in the literature and future research has remained relatively haphazard. In most circumstances, no formal mechanism exists to take the limitations ofthe existing literature (e.g., as noted in a systematic review) and to use this as the basis for encouraging future studies. The development of such a mechanism would certainly be beneficial; for example, it would benefit decision makers by assuring a flow of the information that they need, and it would benefit researchers by providing the opportunity to conduct studies that are of clear relevance to policy.
In the absence of a formal mechanism, various parties have experimented with ways to encourage a more explicit linkage between gaps in the existing evidence and the design of future research. One In terms of the primary study objective, it was noted that the immediate interest of CMS was to obtain clinical data that would allow an informed decision regarding whether and when to cover FDG-PET for individuals with cognitive complaints. Such a decision would be guided by a demonstrated impact of such testing on the health and well-being of Medicare beneficiaries, as well as improved patterns of care (e.g., minimizing wasteful unnecessary testing and treatment). Table I summarizes short-and long-term outcomes relevant to these domains. From a policy-making perspective, the key concern, particularly regarding any hypothesis related to patterns of care, was the impact of the availability of reimbursement for FDG-PET, not merely the impact of the use of FDG-PET on an individual patient, reflecting the upper two quadrants of Table 1 .
To address the primary CMS objective, the following desirable design features were identified:
1. The subjects should be representative of beneficiaries presenting with early cognitive complaints. It was noted that this would be challenging because there is currently no widely accepted validated measure for MCI in the AD research community. 4. The trial should monitor outcomes over a prolonged time period (i.e., several years) with data reporting at pre-specified intervals because patterns of use are likely to change over time; furthermore, impact on several patient outcomes (e.g., nursing home admission) would emerge late, particularly for individuals with milder conditions. 5 . The trial should permit examination of the contribution of FDG-PET beyond clinical evaluation. Notably, if this were the primary study hypothesis, it would require patients to be randomized to receive FDG-PET or not; however, this would be inconsistent with the primary objective of CMS, to determine if availability of reimbursement for FDG-PET has a beneficial effect.
6. The design should permit consideration of emerging imaging approaches (e.g., perfusion magnetic resonance imaging). Again, the issue impacts the basic nature of tire selected study design, and the recommended design would allow this to be incorporated as an ancillary study. 7 . The outcome measures should be valid and compelling to decision makers (i.e., have face validity).
To implement a study, the following feasibility issues were noted:
1. The core design should be defensible as a demonstration project if it is to receive significant CMS support.
2. Patient-and provider-level data are more challenging and expensive to collect than Medicare claims file-based data.
3. Health outcomes are much less likely to be discernible in a study in which allocation is by community instead of by patient; such effects will need to be evaluated in the context of ancillary studies.
4. The study should promote (and should not in any significant way inhibit) further scientific research.
Potential study design
A pragmatic trial (summarized in Figure 1) One possible design approach proposed to address issues in the lower two quadrants (health and well-being in the short-and long term) is to add a survey of patients and caregivers. The survey would include quality of life; depression; anxiety; stress; decisional confidence in diagnosis, prognosis, and treatment; treatment adherence; financial, social, and legal decision making (e.g., advance directives, living wills, and Do Not Resuscitate orders); and cognitive status. Such a study would be an add-on to the core study; the addition is telephone interviews with patents and caregivers. A major caveat of the study is that it would be especially difficult to discern effects on patient health and well-being because only a fraction ofpatients would have FDG-PET, and those that do would be likely to systematically differ from those that do not. Therefore, such a study of the effects on health and well-being would not only require patientlevel data but also patient-level randomization.
Conclusion
We have illustrated how to link a research agenda to unmet information needs. In particular, we have shown how a systematic review revealed important gaps in the literature on FDG-PET for AD. This provided the basis for a conditional coverage decision issued by CMS that included the suggestion for a practical clinical trial. Key aspects of the trial were delineated based on a meeting with various stakeholders and used as the basis for informing a potential study design. While the study itself is of direct relevance to the needs of CMS, multiple opportunities exist for adding on studies to address questions from basic neuroscience to health policy.
In our opinion, this is a good approach to bridging the gap that represents a win for all stakeholders. Industry has greater certainty in approaching research and development investment, payors have a handle on dissemination of innovative technologies that assure good value, clinicians have practical data that are as directly applicable to their patients as possible, and patients have information that wijl allow them to be active participants in improving their own health and well-being. However, the degree to which this mechanism represents a win will only be evident when we work through the next steps of implementing the trial and obtaining results. We anticipate that this will not only serve as a model for setting health policy research priorities but also for implementing policy-relevant studies.
